

come across with altered blood-glucose concentration in patients on TPN feeding who require closer monitoring with complex and dynamic treatment such as insulin. Despite such potential benefits, insulin added to TPN is still controversial due mainly to the potential risk of hypoglycaemia related to its bioavailability.

Purpose Analyse and evaluate the efficacy and safety of fast-acting insulin added to TPN admixtures, in patients with altered glycaemia, followed up by nutrition support pharmacists (NSP).

Material and methods Observational and retrospective study carried out in a General Hospital for 19 months (January 2017 to July 2018). Data was collected from electronic clinical records and the electronic prescribing system. Data collected: total patients on TPN with altered blood-sugar levels followed up by the pharmacy team, patients treated with fast-acting insulin (TPN bag additive), daily (three times) blood-sugar levels (BMs), patient's demographics, hypoglycaemias (blood-sugar levels less than 70 mg/dL) and hyperglycaemias (BMs > 180 mg/dL). Patients admitted to the critical care unit (CCU) or not followed up by the pharmacy team were excluded. We considered target BMs between 140–180 mg/dL. All insulin adjustments were done by NSP.

Results The total number of patients on NPT with altered BMs was 148, and 36 (24.3%) patients required fast-acting insulin therapy. Thirty patients were included in this study due to six being admitted to the CCU. Patients included: 20 were males (66.6%), average age 67 years (range 45–91). Twenty-five (83.3%) patients had hyperglycaemia (≥ 1 BMs > 180 mg/dL) of whom 17 (56.6%) required fast-acting insulin therapy on the TPN bag. Average NPT duration on fast-acting insulin-treated patients was 10 days (range 3–36). Average days BMs > 180 mg/dL: 4.5 (range 1–11). Average BMs > 180 mg/dL: 242 mg/dL (range 181–427 mg/dL; mode: 220 mg/dL). One patient had hypoglycaemia non-insulin-related. None treated with fast-acting insulin had hypoglycaemia.

Conclusion Despite more than half of the patients treated with fast-acting insulin therapy having hyperglycaemia, none of them had hypoglycaemia. On the other hand, a cautious use of the fast-acting insulin TPN bag added could boost hyperglycaemias in our patients. Administering insulin along with TPN continuously appeared to be a safe method, providing a smoother glycaemic profile.

REFERENCES AND/OR ACKNOWLEDGEMENTS

<https://doi.org/10.1177/0148607117722750>

<http://dx.doi.org/10.1136/ejhp-2018-eahpconf.136>

No conflict of interest.

5PSQ-006 USE OF SUBSTITUTE ENZYMATIC TREATMENT AND SUBSTRATE REDUCTION IN GAUCHER DISEASE

V González Rosa*, MI Sierra Torres, S Fernández Espínola, M Zaragoza Rascón, M Pajares Alonso. *Hospital Serranía Ronda, Servicio de Farmacia, Ronda Málaga, Spain*

10.1136/ejhp-2019-eahpconf.439

Background Gaucher disease is included within lipidosis that occur due to mutations in the gene encoding the enzyme β -glucosidase. As a result of this, a fatty substance accumulates, the glucocerebroside that is the cause of disease manifestations such as anaemia, thrombocytopenia, hepatosplenomegaly and bone injuries. Available therapeutic

options include enzyme replacement therapy (ERT) or substrate reduction (SRT) to prevent glucocerebroside accumulation.

Purpose To describe the use of ERT and SRT in patients with Gaucher disease.

Material and methods Retrospective observational study of all patients diagnosed with Gaucher disease in our area, followed up in our hospital and in treatment with ERT or SRT. Respective electronic medical records and analytics were reviewed to collect the following data: sex, age, symptomatology of Gaucher disease at the time of diagnosis, value of chitotriosidase before and after starting treatment, and adverse reactions to it.

Results A total of four patients (two males and two females) with an average age of 50 years were included. All patients had type 1 Gaucher disease (not neuropathic). The initial treatment was miglustat (SRT) in three patients and velaglucerase (ERT) in one of them. The value of chitotriosidase before the start of treatment had a mean value of 11034 nmol/h/mL (7184–12777) and after treatment it was 1536 nmol/h/mL (239–3973).

All the patients presented at the beginning with typical manifestations of type 1 Gaucher disease as bone affection (three), hepatosplenomegaly (three), anaemia (two) and thrombocytopenia (two). Regarding the safety of the SRT, treatment with miglustat was started in three patients. It was finished in two cases due to bone progression and in one case due to poor tolerance (paresthesia, diarrhoea, tremor and weight loss) and the TES was switched to imiglucerase or velaglucerase, which were well tolerated in all patients. All the patients presented improvement in the symptoms of Gaucher disease when starting ERT.

Conclusion TRS with miglustat is a convenient option due to its oral administration, although in three patients who were initially administered, it had to be suspended due to poor tolerance or progression. ERT has been shown to be effective and safe, and, despite not being curative, an improvement and even remission of certain symptoms of the disease has been proven.

REFERENCES AND/OR ACKNOWLEDGEMENTS

https://ejhp.bmj.com/content/21/Suppl_1/A38.1

No conflict of interest.

5PSQ-007 SEBELIPASE ALFA AS ENZYME REPLACEMENT THERAPY IN THREE PAEDIATRIC PATIENTS

C Jimenez Nunez*, J Alvarez Criado, T Perez Robles, P Gabaldon Garnica, C Jimenez Vicente, M Moreno Palomino, P Lucena Martinez, A Herrero Ambrosio. *Hospital Universitario la Paz, Hospital Pharmacy, Madrid, Spain*

10.1136/ejhp-2019-eahpconf.440

Background Lysosomal acid lipase deficiency (LALD) is a rare lysosomal disorder characterised by clinical with dyslipidaemia and steatohepatitis. Sebelipase-alfa is a recombinant human LAL, recently approved for clinical use in LALD.

Purpose Evaluation of the effectiveness and safety of sebelipase-alfa as enzyme replacement therapy in paediatric patients with LALD.

Material and methods Observational, retrospective study included three patients treated with sebelipase-alfa. From clinical history the following data were obtained: age, sex, diagnosis, values of total cholesterol, low-density lipoprotein